Raras
Buscar doenças, sintomas, genes...
Astrocitoma fibrilar
ORPHA:251601CID-10 · C71.9CID-11 · 2A00.0YDOENÇA RARA

É o tipo histológico mais frequente de astrocitoma difuso. É composto principalmente por astrócitos (células cerebrais) cancerosos com aspecto fibroso (fibrilar). A presença de alterações no núcleo das células (atipia nuclear) é um critério para o diagnóstico. No entanto, não há sinais de grande divisão celular (atividade mitótica), morte de tecido (necrose) ou crescimento de novos vasos sanguíneos (proliferação microvascular). A ocorrência ocasional ou em certas regiões de células cancerosas do tipo gemistocítico (células maiores e mais arredondadas) é compatível com o diagnóstico de astrocitoma fibrilar.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É o tipo histológico mais frequente de astrocitoma difuso. É composto principalmente por astrócitos (células cerebrais) cancerosos com aspecto fibroso (fibrilar). A presença de alterações no núcleo das células (atipia nuclear) é um critério para o diagnóstico. No entanto, não há sinais de grande divisão celular (atividade mitótica), morte de tecido (necrose) ou crescimento de novos vasos sanguíneos (proliferação microvascular). A ocorrência ocasional ou em certas regiões de células cancerosas do tipo gemistocítico (células maiores e mais arredondadas) é compatível com o diagnóstico de astrocitoma fibrilar.

Pesquisas ativas
1 ensaio
9 total registrados no ClinicalTrials.gov
Publicações científicas
176 artigos
Último publicado: 2024 May 22
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C71.9
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa2desde 2024
Total histórico176PubMed
Últimos 10 anos17publicações
Pico20164 papers
Linha do tempo
2024Hoje · 2026🧪 1994Primeiro ensaio clínico📈 2016Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição.

IDH2Isocitrate dehydrogenase [NADP], mitochondrialBiomarker tested inAltamente restrito
FUNÇÃO

Plays a role in intermediary metabolism and energy production (PubMed:19228619, PubMed:22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:19228619, PubMed:22416140)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (4)
Citric acid cycle (TCA cycle)Maturation of TCA enzymes and regulation of TCA cycleMitochondrial protein degradationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

D-2-hydroxyglutaric aciduria 2

A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
442.8 TPM
Coração - Ventrículo esquerdo
311.5 TPM
Rim - Medula
273.8 TPM
Linfócitos
186.0 TPM
Fígado
184.7 TPM
OUTRAS DOENÇAS (13)
d-2-hydroxyglutaric aciduria 2anaplastic oligodendrogliomagemistocytic astrocytomaoligoastrocytoma
HGNC:5383UniProt:P48735

Variantes genéticas (ClinVar)

82 variantes patogênicas registradas no ClinVar.

🧬 IDH2: GRCh38/hg38 15q26.1-26.3(chr15:90068508-101888837)x3 ()
🧬 IDH2: NM_002168.4(IDH2):c.800A>G (p.Gln267Arg) ()
🧬 IDH2: GRCh37/hg19 15q26.1-26.3(chr15:90569376-102369410)x1 ()
🧬 IDH2: NM_002168.4(IDH2):c.448G>C (p.Glu150Gln) ()
🧬 IDH2: NM_002168.4(IDH2):c.1081-60C>G ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 23
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 6 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Astrocitoma fibrilar

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

9 ensaios clínicos encontrados, 1 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
17 papers (10 anos)
#1

Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.

Journal of neuropathology and experimental neurology2024 May 22

Ganglioglioma (GG) with anaplasia (anaplastic ganglioglioma) is a rare and controversial diagnosis. When present, anaplasia involves the glial component of the tumor, either at presentation or at recurrence. To date, most published cases lack molecular characterization. We describe the histologic and molecular features of 3 patients presenting with BRAF p. V600E-mutant GG (CNS WHO grade 1) with high-grade glial transformation at recurrence. The tumors occurred in pediatric patients (age 9-16 years) with time to recurrence from 20 months to 7 years. At presentation, each tumor was low-grade, with a BRAFV600E-positive ganglion cell component and a glial component resembling pleomorphic xanthoastrocytoma (PXA) or fibrillary astrocytoma. At recurrence, tumors resembled anaplastic PXA or high-grade astrocytomas without neuronal differentiation. CDKN2A homozygous deletion (HD) was absent in all primary tumors. At recurrence, 2 cases acquired CDKN2A HD; the third case showed loss of p16 and MTAP immunoexpression, but no CDKN2A/B HD or mutation was identified. By DNA methylation profiling, all primary and recurrent tumors either grouped or definitely matched to different methylation classes. Our findings indicate that malignant progression of the glial component can occur in GG and suggest that CDKN2A/B inactivation plays a significant role in this process.

#2

Diagnosis and Treatment of Sylvian Aqueduct Syndrome.

The Journal of craniofacial surgery2024 Feb 16

Sylvian aqueduct syndrome is a rare complication after ventriculoperitoneal (V-P) shunt surgery and is not easily diagnosed. A 26-year-old male with obstructive hydrocephalus due to tectal glioma was treated with a V-P shunt surgery in another hospital. After the surgery, the patient developed an intractable disturbance of consciousness. When the V-P shunt pressure was raised or lowered, the patient's consciousness disorder still could not be improved. The patient was diagnosed with Sylvian aqueduct syndrome, a rare complication after V-P shunt operation. The paper clarifies the treatment experience with simultaneous endoscopic third ventriculostomy (ETV) and tectum gliomas biopsy, postoperative pathology suggestive of fibrillary astrocytoma; after surgery, the Sylvian aqueduct syndrome was cured and the patient recovered well. The preferred treatment for obstructive hydrocephalus caused by tumors in the Pineal region is the ETV operation. If an ETV operation and biopsy operation are performed simultaneously, more details need to be noted.

#3

Awake Surgery With Visual Pathway Mapping in Low Grade Glioma Surgery.

Cureus2022 Feb

The visual pathway and its defects have been thoroughly studied in clinical correlation to temporal lobe lesions related to epilepsy and traumatic lesions. Nevertheless, its clinical correlation and other decision-making have not been addressed regarding neoplastic lesions. We present a case report of a 28-year-old man with a one-year history of generalized seizures and left superior homonymous quadrantanopia, with no other neurological disturbance on physical examination. According to diffusion tensor imaging tractography, MRI demonstrated a non-enhancing, right temporal lesion disrupting the visual pathway. An awake surgery with direct cortical electrostimulation of visual pathways was performed with subtotal resection of the tumor to preserve visual function, confirmed with postoperative MRI. Histopathological studies revealed a fibrillary astrocytoma. Surgical technique aided with intraoperative cortical and subcortical stimulation involving low-grade gliomas in eloquent areas is an exceptionally suitable procedure for complex cases where the visual pathway is compromised. Our objective is to describe how intraoperative mapping of visual function is performed in our institution and to comment on the relevant technical nuances, which can serve as a practical guideline for young neurosurgeons, as no previous cases have been reported in our country.

#4

Remission of Pediatric Diffuse Intrinsic Pontine Glioma: Case Report and Review of the Literature.

Journal of pediatric neurosciences2021

Diffuse midline glioma (DMG) is one of the most aggressive pediatric tumors. Approximately 60% of pediatric DMG patients die within the first year of diagnosis. Complete clinical and radiological remission of DMG is extremely rare. The objective of this study was to describe a case of remission of pediatric DMG and to compare with similar cases published so far. DMG was diagnosed in a 2-year-old girl who presented with brainstem and increased intracranial pressure manifestations. Ventriculoperitoneal shunt and chemotherapy-based treatment were offered. From the diagnosis, in spite of progressive enlargement of the tumoral lesion, her clinical condition improved remarkably. After the end of chemotherapy, progressive and gradual imagiological improvements occurred. At the end of the 60th month of follow-up, she was asymptomatic with total remission. Six pediatric DMG cases, from birth to the age of 3, in whom remission occurred were found in the literature. Histology sample was available in two of them (fibrillary astrocytoma-WHO Grade II and anaplastic astrocytoma-WHO Grade III). None received chemotherapy or radiotherapy. Remission of pediatric DMG is extremely rare and reinforces the biological heterogeneity of the tumor. In the absence of reliable predictors of prognosis, offering the best supportive treatment, including neurosurgical interventions should be considered in similar cases.

#5

Prognostic Factors Associated With Survival in Patients With Diffuse Astrocytoma.

Frontiers in surgery2021

Background: Diffuse astrocytoma (DA) is a rare disease with inadequately understood epidemiological characteristics and prognosis. Identification of the factors associated with the survival in DA patients is therefore necessary. In this study, we aim to investigate the clinicopathological characteristics of DA to delineate factors influencing the survival of DA. Methods: A population-based cohort study was conducted, utilizing prospectively extracted data from the Surveillance, Epidemiology and End Results (SEER) database. Patients with histological diagnosis of DA in the SEER database from 1973 to 2017 were included. Results: A total of 799 participants with DA were included, consisting of 95.9% fibrillary astrocytoma and 4.1% protoplasmic variants. The average age of participants was 41.9 years, with 57.2% being male. The majority of the population was white (87.5%). More than half (53.9%) of the patients were married. DA arose mostly in the cerebrum (63.8%). Around 71.6% of the population had received surgical treatment. The overall 1-, 3-, 5-, and 10-year survival rate were 73.7, 55.2, 49.4, and 37.6%, respectively. Kaplan-Meier analysis showed that age at diagnosis, marital status, primary tumor site, tumor size, and surgery was possibly associated with cancer-specific survival (CSS) (p < 0.05). Multivariate Cox proportional hazard analysis indicated that surgery was a protective factor whereas older age, larger tumor size, and tumor in the brainstem were harmful factors for patients with DA. Moreover, a nomogram predicting 5- and 10-year survival probability for DA was developed. Conclusions: Age, primary tumor site, tumor size, and surgery were associated with the survival of patients with DA.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC18 artigos no totalmostrando 17

2024

Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.

Journal of neuropathology and experimental neurology
2024

Diagnosis and Treatment of Sylvian Aqueduct Syndrome.

The Journal of craniofacial surgery
2022

Awake Surgery With Visual Pathway Mapping in Low Grade Glioma Surgery.

Cureus
2021

Prognostic Factors Associated With Survival in Patients With Diffuse Astrocytoma.

Frontiers in surgery
2021

Remission of Pediatric Diffuse Intrinsic Pontine Glioma: Case Report and Review of the Literature.

Journal of pediatric neurosciences
2021

Can permanent cell lines originate from low-grade astrocytomas: overgrowth of "glia-like" cells in pilocytic and fibrillary (diffuse) astrocytoma cultures.

Bratislavske lekarske listy
2020

The expression level of cannabinoid receptors type 1 and 2 in the different types of astrocytomas.

Molecular biology reports
2020

1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.

Annals of diagnostic pathology
2019

IDH-1 polymorphisms in pilocytic astrocytomas.

Annals of diagnostic pathology
2017

A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016.

Journal of neurosciences in rural practice
2018

Mortality in children with low-grade glioma or glioneuronal tumors: A single-institution study.

Pediatric blood &amp; cancer
2017

Multimodal Imaging of Patients With Gliomas Confirms 11C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy.

Molecular imaging
2017

A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma.

The Journal of clinical investigation
2016

MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
2016

MORPHOLOGICAL PATTERN AND FREQUENCY OF CENTRAL NERVOUS SYSTEM TUMOURS IN CHILDREN.

Journal of Ayub Medical College, Abbottabad : JAMC
2016

Treatment and Outcome in 65 Children with Optic Pathway Gliomas.

World neurosurgery
2016

Effect of cognitive rehabilitation in a case of thalamic astrocytoma.

Applied neuropsychology. Adult
Ver todos os 18 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Astrocitoma fibrilar.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Astrocitoma fibrilar

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    Journal of neuropathology and experimental neurology· 2024· PMID 38699943mais citado
  2. Diagnosis and Treatment of Sylvian Aqueduct Syndrome.
    The Journal of craniofacial surgery· 2024· PMID 38363289mais citado
  3. Awake Surgery With Visual Pathway Mapping in Low Grade Glioma Surgery.
    Cureus· 2022· PMID 35308657mais citado
  4. Remission of Pediatric Diffuse Intrinsic Pontine Glioma: Case Report and Review of the Literature.
    Journal of pediatric neurosciences· 2021· PMID 34316300mais citado
  5. Prognostic Factors Associated With Survival in Patients With Diffuse Astrocytoma.
    Frontiers in surgery· 2021· PMID 34722621mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:251601(Orphanet)
  2. MONDO:0016688(MONDO)
  3. GARD:20708(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q953330(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Astrocitoma fibrilar
Compêndio · Raras BR

Astrocitoma fibrilar

ORPHA:251601 · MONDO:0016688
CID-10
C71.9 · Neoplasia maligna do encéfalo, não especificado
CID-11
Ensaios
1 ativos
MedGen
UMLS
C0334582
Repurposing
2 candidatos
carmustineDNA alkylating agent|DNA inhibitor
temozolomideDNA alkylating agent
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades